Medifast (MED) Change in Accured Expenses (2010 - 2026)

Medifast (MED) has 17 years of Change in Accured Expenses data on file, last reported at -$1.4 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 75.84% year-over-year to -$1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.4 million (up 22.77% YoY) and the FY2025 annual result came in at -$23.9 million, up 31.67% from the prior year.
• Change in Accured Expenses advanced to -$1.4 million in Q1 2026, from -$4.3 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of -$364000.0 in Q4 2023 to a low of -$21.9 million in Q1 2023.
• A 5-year average of -$7.9 million and a median of -$6.1 million in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses surged 97.63% — and 2024, when it slumped 2982.14%.
• Tracing MED's Change in Accured Expenses over 5 years: stood at -$15.3 million in 2022, then surged by 97.63% to -$364000.0 in 2023, then tumbled by 2982.14% to -$11.2 million in 2024, then soared by 61.65% to -$4.3 million in 2025, then soared by 66.33% to -$1.4 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.4 million (Q1 2026), -$4.3 million (Q4 2025), and -$516000.0 (Q3 2025), per Business Quant data.